Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $14.65

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report)'s share price gapped up before the market opened on Wednesday . The stock had previously closed at $14.65, but opened at $15.10. Nurix Therapeutics shares last traded at $15.02, with a volume of 55,095 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Royal Bank of Canada raised their price objective on shares of Nurix Therapeutics from $22.00 to $23.00 and gave the company an "outperform" rating in a report on Thursday, April 11th. Morgan Stanley raised their price objective on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an "equal weight" rating in a report on Monday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, April 9th. HC Wainwright reduced their price objective on shares of Nurix Therapeutics from $35.00 to $19.00 and set a "buy" rating on the stock in a report on Tuesday, February 20th. Finally, Robert W. Baird raised their price objective on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an "outperform" rating in a report on Thursday, April 11th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $21.33.

Nurix Therapeutics Stock Down 3.9 %

The stock has a market capitalization of $692.03 million, a PE ratio of -5.29 and a beta of 2.06. The business's 50-day moving average is $13.02 and its two-hundred day moving average is $9.40.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). The business had revenue of $15.16 million during the quarter, compared to analyst estimates of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. As a group, analysts anticipate that Nurix Therapeutics, Inc. will post -3.28 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,812 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24. Following the transaction, the chief financial officer now directly owns 68,333 shares in the company, valued at $684,696.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 10,817 shares of company stock worth $100,256 over the last ninety days. 9.80% of the stock is currently owned by company insiders.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Credit Suisse AG lifted its stake in shares of Nurix Therapeutics by 7.9% during the second quarter. Credit Suisse AG now owns 15,619 shares of the company's stock valued at $197,000 after buying an additional 1,145 shares during the period. Barclays PLC lifted its stake in shares of Nurix Therapeutics by 1.9% during the fourth quarter. Barclays PLC now owns 68,739 shares of the company's stock valued at $709,000 after buying an additional 1,272 shares during the period. Virtus ETF Advisers LLC lifted its stake in shares of Nurix Therapeutics by 14.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,356 shares of the company's stock valued at $107,000 after buying an additional 1,345 shares during the period. Rhumbline Advisers lifted its stake in shares of Nurix Therapeutics by 4.9% during the first quarter. Rhumbline Advisers now owns 33,511 shares of the company's stock valued at $469,000 after buying an additional 1,573 shares during the period. Finally, Principal Financial Group Inc. increased its position in Nurix Therapeutics by 16.3% during the first quarter. Principal Financial Group Inc. now owns 12,804 shares of the company's stock worth $114,000 after purchasing an additional 1,793 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.